{
    "clinical_study": {
        "@rank": "23607", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic\n      polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis", 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study.  Patients are stratified by\n      participating institution.\n\n      One group receives copolymer 1, a mixture of synthetic polypeptides composed of 4 amino\n      acids, subcutaneously each day for 2 years.\n\n      The other group receives an injection of placebo daily for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Clinically or laboratory-supported definite multiple sclerosis\n\n          -  Neurologically stable for at least 30 days prior to entry Expanded Disability Status\n             Scale score no greater than 5\n\n          -  At least 2 documented relapses within 2 years prior to entry Onset of first relapse\n             at least 1 year prior to randomization\n\n        --Prior/Concurrent Therapy--\n\n          -  Biologic therapy: No prior copolymer 1\n\n          -  Immunosuppressive therapy: No prior cytotoxic immunosuppressives, i.e.: Azathioprine\n             Cyclophosphamide Cyclosporine At least 30 days since corticosteroids\n\n          -  Radiotherapy: No prior lymphoid irradiation\n\n        --Patient Characteristics--\n\n          -  Not HIV or HTLV-I seropositive No insulin-dependent diabetes mellitus No Lyme disease\n             No requirement for aspirin or chronic nonsteroidal anti-inflammatory drugs No\n             pregnant or nursing women Adequate contraception required of fertile women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "250", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004814", 
            "org_study_id": "199/12023", 
            "secondary_id": "UMB-55901"
        }, 
        "intervention": {
            "intervention_name": "copolymer 1", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Copolymer 1"
        }, 
        "keyword": [
            "multiple sclerosis", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Maryland", 
            "last_name": "Kenneth P. Johnson", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004814"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Maryland", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1991", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1997"
    }, 
    "geocoordinates": {}
}